Erimos Pharmaceuticals Adds Three Oncology Researchers To Advisory Board
Posted August 15, 2006
RALEIGH, N.C. — Three oncology researchers have joined the advisory board of
, which is focused on discovery, development and commercialization of cancer drugs.
The new members are Jeffrey Trent, Daniel Von Hoff and Steven Weitman.
Trent is president and scientific director of the Translational Genomics Research Institute. He spent 10 years at the National Institutes of Health and founded the Division of Intramural Research of the National Human Genome Research Institute.
Von Hoff is senior investigator and executive vice president of Tgen. He has been involved in development of numerous agents used to fight cancer.
Weitman, a pediatric oncologist, has served as chief medical officer at ILEX Oncology and at one time was head of the pre-clinical section at the Institute for Drug Development.
Erimos plans to launch a Phase I study of its first drug candidate before the end of this year.